{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"ZLYNXDIDWUWASO-UHFFFAOYSA-N","prefName":"Cannabicitrán (CBT-C)","symbol":"CBT","iupacName":null,"aliases":["CBT-C","CBT","Cannabicitran"],"cas":"11003-36-4","pubchemCid":"11551959","chebiId":null,"smiles":"CCCCCC1=CC(=C2C(=C1)OC(C3=C2C(C(CC3)(C)O)O)(C)C)O","molecularFormula":"C21H30O4","molecularWeight":346.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/11551959"}},"classification":{"family":"mineur","familyLabel":"Fitocannabinoide menor","origin":"natural","originLabel":"Naturel","structuralClassFr":null},"originSynthesis":{"heading":"Vía biosintética","summaryFr":"Vía biosintética no enteramente caracterizada - esqueleto tetracíclico benzo[c]cromeno saturado, isómero estructural del THCA/CBLA","originNote":"Planta (cannabinoide tetracíclico benzo[c]cromeno)","discovered":"1971"},"pharmacology":{"summaryFr":"El cannabicitrán (CBT-C) fue caracterizado por Bercht et al. (1973) como isómero estructural tetracíclico del THCA/CBLA. Esqueleto benzo[c]cromeno saturado. Presente en estado de trazas en ciertas variedades (Cannabis sativa indica). Actividad CB1/CB2 despreciable. Francia: su estructura tetracíclica lo hace caer bajo la **cláusula benzo[c]cromeno saturado** introducida por la **Decisión ANSM del 22 de mayo de 2024** - confirmación pendiente de validar sobre el texto íntegro de la decisión.","receptorSummaryFr":"Actividad CB1/CB2 despreciable in vitro; in vivo, perfil no psicótropo","binding":[{"target":"CB1","efficacy":"modulator","relativeActivity":8,"reported":null,"confidence":"low"},{"target":"CB2","efficacy":"modulator","relativeActivity":5,"reported":null,"confidence":"low"}],"references":[]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calma","description":"Relajación del cuerpo y de la mente; menos ruido mental, sin somnolencia marcada.","intensity":25},{"key":"focus","label":"Claridad","description":"Atención sostenida y pensamiento claro; lucidez funcional, sin euforia.","intensity":30},{"key":"sleep","label":"Sueño","description":"Efecto sedante: favorece la conciliación del sueño y la continuidad del sueño profundo.","intensity":15},{"key":"appetite","label":"Apetito","description":"Estimulación del hambre y de la apreciación gustativa (efecto «munchies»).","intensity":10},{"key":"uplift","label":"High","description":"Euforia e intensidad sensorial; percepción del tiempo y del espacio modificada.","intensity":5}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"controlled-clause","scheduleLabel":"Estupefaciente: cláusula genérica","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No listado específicamente","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Estupefaciente: cláusula benzo[c]cromeno (Decisión ANSM 22/05/2024)","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[],"meta":{"slug":"cbt","url":"https://es.phytogrammes.com/wiki/cbt","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"medium","dataCompletenessPct":70,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}